SCHEMBL3244840

SCHEMBL3244840

COc1ccc(S(=O)(=O)N(Cc2nnnn2C)c2ccc(Cl)cc2Cc2c(F)cccc2F)cc1OC

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PKM P14618 2/20 0.41
HCRTR2 O43614 5/20 0.40
HCRTR1 O43613 4/20 0.40
CCR1 P32246 1/20 0.39
CCR2 P41597 1/20 0.39
CCR4 P51679 1/20 0.39
POLB P06746 1/20 0.39
MCOLN3 Q8TDD5 1/20 0.39
MAPT P10636 4/20 0.36
TP53 P04637 1/20 0.36
SMN1; SMN2 Q16637 3/20 0.34
HTT P42858 2/20 0.34
ALDH1A1 P00352 2/20 0.34
HPGD P15428 1/20 0.34
PDE4A P27815 1/20 0.34
PDE4B Q07343 1/20 0.34
PDE4C Q08493 1/20 0.34
PDE4D Q08499 1/20 0.34
HIF1A Q16665 2/20 0.34
TSHR P16473 2/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3251397 0.92 PKM (0.40) PKMHCRTR2HCRTR1CCR1CCR2
SCHEMBL3244577 0.87 PKM (0.42) PKMHCRTR2HCRTR1CCR1CCR2
SCHEMBL3250490 0.86 CCR1 (0.40) CCR1CCR2CCR4POLBMCOLN3
SCHEMBL3253916 0.86 PKM (0.41) PKMHCRTR2HCRTR1POLBMCOLN3
SCHEMBL3247064 0.86 PKM (0.41) PKMHCRTR2HCRTR1POLBMCOLN3
SCHEMBL3252477 0.83 PKM (0.45) PKMHCRTR2HCRTR1POLBMCOLN3
SCHEMBL3251584 0.83 PKM (0.42) PKMHCRTR2HCRTR1POLBMCOLN3
SCHEMBL8273307 0.83 HCRTR2 (0.51) PKMHCRTR2HCRTR1POLBMCOLN3
SCHEMBL3253554 0.83 PKM (0.37) PKMHCRTR2HCRTR1POLBMCOLN3
SCHEMBL3254869 0.83 PKM (0.40) PKMHCRTR2HCRTR1POLBMCOLN3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1776347-B1 SULPHONAMIDE DERIVATIVES, THEIR PREPARATION AND THEIR THERAPEUTIC APPLICATION SANOFI AVENTIS (FR) 2010-05-26 EP disclosed
US-7396958-B2 Sulphonamide derivatives, their preparation and their therapeutic application SANOFI AVENTIS (FR) 2008-07-08 US disclosed
US-7396958-B2 Sulphonamide derivatives, their preparation and their therapeutic application SANOFI AVENTIS (FR) 2008-07-08 US disclosed
US-7396958-B2 Sulphonamide derivatives, their preparation and their therapeutic application SANOFI AVENTIS (FR) 2008-07-08 US disclosed
US-20070185136-A1 SULPHONAMIDE DERIVATIVES, THEIR PREPARATION AND THEIR THERAPEUTIC APPLICATION SANOFI-AVENTIS (FR) 2007-08-09 US disclosed
US-20070185136-A1 SULPHONAMIDE DERIVATIVES, THEIR PREPARATION AND THEIR THERAPEUTIC APPLICATION SANOFI-AVENTIS (FR) 2007-08-09 US disclosed
US-20070185136-A1 SULPHONAMIDE DERIVATIVES, THEIR PREPARATION AND THEIR THERAPEUTIC APPLICATION SANOFI-AVENTIS (FR) 2007-08-09 US disclosed
EP-1776347-A1 SULPHONAMIDE DERIVATIVES, THEIR PREPARATION AND THEIR THERAPEUTIC APPLICATION Sanofi-Aventis (FR) 2007-04-25 EP disclosed
WO-2006024779-A1 SULPHONAMIDE DERIVATIVES, THEIR PREPARATION AND THEIR THERAPEUTIC APPLICATION SANOFI-AVENTIS (FR) 2006-03-09 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070185136-A1 SULPHONAMIDE DERIVATIVES, THEIR PREPARATION AND THEIR THERAPEUTIC APPLICATION HCRTR2, GIPR, SSTR2 PKM 2524/4885HCRTR2 1/4885HCRTR1 6/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.